AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01265264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose administered daily for 84 days.
Study NCT03596749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer Carbonate
Description: Sevelamer carbonate 1600mg (p.o. b.i.d) with meals
Study NCT02154828 — intervention group
Intervention type: BEHAVIORAL
Intervention: Integrative practices
Study NCT00668993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT - the Emotional Freedom technique
Description: EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published
Study NCT03345966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bmi-1 antibody
Description: B-lymphoma Moloney murine leukemia virus insertion region-1
Study NCT03763513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Extracorporeal Shock Wave Therapy=ESWT
Study NCT03763513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: Extracorporeal Shock Wave Therapy=ESWT
Study NCT03763513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping Application
Description: Kinesiotaping=KT (CT)
Study NCT00771589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Knee Prosthesis
Description: Motorized External Knee Prosthesis for above knee amputees.
Study NCT02235506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femoral sciatic
Description: After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
Study NCT01693445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OIS (Oxaliplatin, Irinotecan, S-1)
Description: Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level.
Study NCT04781075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Scale
Description: Maximum Daily Pain Scale will be recorded daily until discharge (typically under 7 days)
Study NCT04781075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Scale
Description: Maximum Daily Pain Scale will be recorded daily until discharge (typically under 7 days)
Study NCT04781075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: Given at the beginning of the surgery for post-operative pain management
Study NCT04781075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Given at the beginning of the surgery for post-operative pain management
Study NCT00700856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: add-on pioglitazone
Description: participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
Study NCT00700856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: add-on sulphonylurea
Description: participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
Study NCT03151889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
Study NCT02773329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensor-based interactive exercise (game-based exercise)
Description: This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
Study NCT02997241 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: OncoCare
Description: Personalized monitoring
Study NCT02997241 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OncoCare
Description: Personalized monitoring
Study NCT02997241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy for colorectal carcinoma
Description: chemotherapy for colorectal carcinoma
Study NCT03565367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: gadolinium enhanced MRI
Study NCT03565367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV
Study NCT03565367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03565367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study NCT02773329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention without game-based exercise
Description: Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
Study NCT00976430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone marrow derived stem cells transplant
Description: Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
Study NCT03088969 — intervention group
Intervention type: OTHER
Intervention: questionnaire RTWSE
Description: The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
Study NCT04953871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF Inhibitor
Description: TNF inhibitors are widely used in patients with spondyloarthritis
Study NCT00605267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg once daily oral dose
Study NCT00605267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole (Arimidex)
Description: 1 mg once daily oral dose
Study NCT02585661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy product fortified with enriched Fe-54 salt (1)
Description: 2.5mg of Fe per 100g of product
Study NCT02585661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy product fortified with enriched Fe-57 salt (2)
Description: 2.5mg of Fe per 100g of product
Study NCT00605267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin acetate (Zoladex)
Description: 3.6mg/month depot injection
Study NCT04240795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low lubricity (LL) hydrogels containing fibre-based beads
Description: The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
Study NCT01003002 — intervention group
Intervention type: DRUG
Intervention: Levodopa (delivered intravenously)
Description: One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
Study NCT00605267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (Zoladex)
Description: 3.6mg/month depot injection
Study NCT03064880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SV maximization
Description: Voluven solution 250 mL infusion per 5 minutes up to the platau of Flank-starling law: status to SV change \< 10% and maintained for 20 minutes
Study NCT04056182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine 0.18 MG
Description: Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
Study NCT00819507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinonide
Description: Fluocinonide 0.1% cream topical daily for two weeks
Study NCT01805934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBLF
Description: The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
Study NCT01805934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RA
Description: The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
Study NCT04240795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low lubricity (LL) hydrogels containing fibre-based beads
Description: The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
Study NCT04240795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low lubricity (LL) hydrogels containing fibre-based beads
Description: The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
Study NCT04012164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: 5ml blood sampling
Study NCT04012164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stool collection
Description: self stool collection (2g)
Study NCT04012164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participatory activity and contact investigation
Description: 30 human subjects will self-report daily activities and contacts with selected wild and domesticated animals for five months.
Study NCT04012164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthropological and historical interviews
Description: Oral interviews on current and past practices and engagements with wild and domesticated animals will be conducted with the 30 human subjects who are recruited to self-report their activities (Participatory activity and contact investigation) and to provide blood and stool samples. Another 30 human subjects will be recruited only to participate in the same type of interviews, addressing past and present activities and relations with wild and domesticated animals.
Study NCT02325869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bell Balloon Catheter
Description: An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
Study NCT03140215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask insertion (Baska)
Study NCT02244151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl® diario
Description: Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
Study NCT02244151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl® daily
Description: Decapeptyl® daily OPU 36 hrs after GnRH administration
Study NCT02159807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.
Study NCT02159807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 20 micrograms routinely administered in combination in the spinal anesthetic
Study NCT05312957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: Group ESP (Arm 1)The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected .When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed.Then, 20 ml of 0.25% bupivacaine was administered to this area, Group Control (Arm 2) :No intervention
Study NCT00950170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laboratory Tests
Description: Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
Study NCT02479789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT02479789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01254669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BNI-brief Negotiated Interview
Description: use of a cognitive behavioral intervention to improve uptake of HPV vaccine
Study NCT01054027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% phenylephrine and 0.2% cyclopentolate
Description: given as drops, prior to eye exam
Study NCT01054027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% phenylephrine and 0.2% cyclopentolate
Description: given as drops, prior to eye exam
Study NCT03429920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Q CAN PLUS
Description: Active powder with fermented soy , 2 pouches per day, each pouch contains 12-15 gms of fermented soy
Study NCT03429920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sprouted brown rice protein with flavor (provided by BESO Biological Research, Inc.)
Study NCT03730597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reverse shoulder arthroplasty
Description: prosthesis implantation
Study NCT03140215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask insertion (I-gel )
Study NCT02081755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months
Study NCT02081755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
Study NCT01571063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, 2.100 IU/d p.o.
Study NCT02063841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lead-free protective drape containing bismuth and antimony (RADPAD®)
Study NCT02063841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sterile identical sham drape
Study NCT01571063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, 2.100 IU/d p.o.
Study NCT02081755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
Study NCT02081755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: Myfortic®: 360 mg to 1080 mg BID for 12 months
Study NCT02081755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept
Description: CellCept: 500 mg to 1500 mg BID for 12 months
Study NCT02081755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imuran
Description: 0.5 mg/kg to 2 mg/kg QD for 12 months
Study NCT03540550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet based on inulin-rich vegetables
Description: During two weeks, healthy subjects were instructed to adhere to a controlled diet based on ITF-rich vegetables (±15 g ITF/day).
Study NCT02043340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
Study NCT01571063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tbl. p.o.
Study NCT01571063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Tbl. p.o.
Study NCT00600171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M
Description: GW642444M
Study NCT00600171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mulit-dose dry powder inhaler
Study NCT02367521 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)
Description: LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.~Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength.
Study NCT02367521 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Comparator: Sham Treatment
Description: Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
Study NCT03129308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: 4.5ml of blood will be collected and analyzed for the presence of cutaneous autoantibodies (indirect immunofluorescence, desmoglein1/3, BPAG1/2, collagenVII, and envoplakin ELISA)
Study NCT02043340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASER
Description: LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
Study NCT02043340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
Study NCT02439359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF-301
Description: Dose escalation
Study NCT02439359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03059355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)
Study NCT03059355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMMSCs
Description: Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)
Study NCT03059355 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single administration of placebo delivered via peripheral intravenous infusion.
Study NCT02726542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Norditropin (growth hormone) given by injection using a pen-device
Study NCT01009372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPP
Description: Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
Study NCT03982134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a humanized IgG4 antibody